Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by University of Padova.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Padova
ClinicalTrials.gov Identifier:
NCT00742339
First received: August 26, 2008
Last updated: August 4, 2011
Last verified: August 2011
  Purpose

From 1999, several studies have showed that the use of vasoconstrictors in association with albumin are effective in the treatment of hepatorenal syndrome (HRS). The rationale of the use of vasoconstrictors together with albumin in the treatment of this severe complication of portal hypertension in patients with cirrhosis is to correct the reduction of the effective circulating volume due to the splanchnic arterial vasodilatation.In most of these studies terlipressin, a derivate of vasopressin, has been used as vasoconstrictor as intravenous boluses moving from an initial dose of 0.5-1 mg/4 hr. In some studies midodrine, an alpha-adrenergic agonist, given by mouth has been used as vasoconstrictor at a dose ranging from 2.5 up to 12.5 tid together with octreotide, an inhibitor of the release of glucagon, given subcutaneously at a dose ranging from 10 µg upt to 200 µg tid. To the day, there isn't a study comparing terlipressin + albumin versus midodrine + octreotide + albumin in the treatment of HRS in patients with cirrhosis.Thus, the aim of the study is to compare terlipressin + albumin vs midodrine + octreotide + albumin in the treatment of the HRS in patients with cirrhosis.


Condition Intervention Phase
Cirrhosis
Hepatorenal Syndrome
Drug: Terlipressin plus albumin
Drug: Midodrine plus octreotide plus human albumin
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome (HRS): An Open Multicentric Randomized Study

Resource links provided by NLM:


Further study details as provided by University of Padova:

Primary Outcome Measures:
  • The primary end-point of the study is the complete reform of the renal function (serum creatinine < 1.5 mg/dl. The primary end point will be evaluated at the end of the treatment. [ Time Frame: The treatment will be continued for a maximum of 15 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: May 2005
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Fifty patients with cirrhosis and HRS will be randomly assigned to arm 1.
Drug: Terlipressin plus albumin
The terlipressin will be give at the initial dose of 3 mg/24 hours by intravenous continuous infusion. If during the following 48 hours the serum value of creatinine will not change or will go down less than 25%, the dose of terlipressin will be increased to 6 mg/24 hours. If no response will ensue, the dose of terlipressin will be increased to the maximal dose of 12 mg/24 hours. Twenty percent human albumin solution will be administrate together with terlipressin at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
Experimental: 2
Fifty patients with cirrhosis and HRS will be randomly assigned to arm 2.
Drug: Midodrine plus octreotide plus human albumin
Midodrine will be give orally at the initial dose 7.5 tid together with octreotide at the initial dosage of 100 µg subcutaneously tid. If during the following 96 hours the serum value of creatinine will not change or will go down less than 25%, the dose of midodrine will be increased to 12.5 mg tid Twenty percent human albumin solution will be administrate together with midodrine and octreotide at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with cirrhosis and diagnosis of HRS type 1 or 2,serum creatinine > 2.5 mg/dl

Exclusion Criteria:

  • Diagnosis of HCC with a staging beyond the Milan Criteria di Milano
  • Septic shock (systolic arterial pressure < 90 mmHg
  • Significant heart or respiratory failure
  • Peripheral arteriophaty clinically significant
  • Previous heart stroke or significant alteration of the ECG
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00742339

Contacts
Contact: Paolo Angeli, Md, PhD +390498218676 pangeli@unipd.it

Locations
Italy
Dept. of Clinical and Experimental Medicine, University of Padova Recruiting
Padova, Italy, 35100
Sub-Investigator: Silvano Fasolato, MD         
Sponsors and Collaborators
University of Padova
  More Information

Publications:
Responsible Party: Paolo Angeli, MD, PhD, Dept. of Clinical and Experimental Medicine, University of Padova, Italy
ClinicalTrials.gov Identifier: NCT00742339     History of Changes
Other Study ID Numbers: 1264P
Study First Received: August 26, 2008
Last Updated: August 4, 2011
Health Authority: Italy: Ministry of Health

Keywords provided by University of Padova:
cirrhosis
hepatorenal syndrome
terlipressin
midodrine
octreotide
human albumin
effective circulating volume
The criteria which will be used for the diagnosis of HRS will be the criteria which were recently published by the International Ascites Club
Patients with cirrhosis and type 2 HRS only with serum creatinine value > 2.5 mg/dl
All patients with cirrhosis and type 1 HRS

Additional relevant MeSH terms:
Liver Cirrhosis
Hepatorenal Syndrome
Syndrome
Liver Diseases
Digestive System Diseases
Kidney Diseases
Urologic Diseases
Disease
Pathologic Processes
Octreotide
Terlipressin
Lypressin
Midodrine
Albunex
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Antihypertensive Agents
Cardiovascular Agents
Vasoconstrictor Agents
Hemostatics
Coagulants
Hematologic Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents

ClinicalTrials.gov processed this record on September 16, 2014